Epigenetic therapeutic strategies in pancreatic cancer

Int Rev Cell Mol Biol. 2024;383:1-40. doi: 10.1016/bs.ircmb.2023.10.002. Epub 2024 Jan 24.ABSTRACTPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid malignancies, characterized by its aggressiveness and metastatic potential, with a 5-year survival rate of only 8-11%. Despite significant improvements in PDAC treatment and management, therapeutic alternatives are still limited. One of the main reasons is its high degree of intra- and inter-individual tumor heterogeneity which is established and maintained through a complex network of transcription factors and epigenetic regulators. Epigenetic drugs, have shown promising preclinical results in PDAC and are currently being evaluated in clinical trials both for their ability to sensitize cancer cells to cytotoxic drugs and to counteract the immunosuppressive characteristic of PDAC tumor microenvironment. In this review, we discuss the current status of epigenetic treatment strategies to overcome molecular and cellular PDAC heterogeneity in order to improve response to therapy.PMID:38359967 | DOI:10.1016/bs.ircmb.2023.10.002
Source: International Review of Cell and Molecular Biology - Category: Cytology Authors: Source Type: research